Abstract
Several studies have evaluated the clinical effectiveness of endocrine therapy alone in women aged 70 years or over and who are fit for surgery. To identify and review the evidence from randomised trials comparing primary endocrine therapy (endocrine therapy alone) to surgery, with or without adjuvant endocrine therapy, in the management of women aged 70 years or over with operable breast cancer. For this update, the Cochrane Breast Cancer Group Specialised Register was searched 13th November 2007 using the codes for "early breast cancer", "endocrine therapy", "psychosocial" or "surgery". Randomised trials comparing primary endocrine therapy with surgery, with or without adjuvant endocrine therapy, in the management of women aged 70 years or over with early breast cancer and who are fit for surgery. Studies were assessed for eligibility and quality, and data from published trials were extracted by two independent reviewers. Hazard ratios were derived for time‐to‐event outcomes, where possible, and a fixed‐effect model was used for meta‐analysis. Toxicity and quality‐of‐life data were extracted, where present. Where outcome data were not available, trialists were contacted and unpublished data requested. Seven eligible trials were identified of which six had published time‐to‐event data and one was published only in abstract form with no usable data. The quality of the allocation concealment was adequate in three studies and unclear in the remainder. In each case the endocrine therapy used was tamoxifen. Data, based on an estimated 869 deaths in 1571 women, were unable to show a statistically significant difference in favour of either surgery or primary endocrine therapy in respect of overall survival. However, there was a statistically significant difference in terms of progression‐free survival, which favoured surgery with or without endocrine therapy. The hazard ratios (HR) for overall survival were: 0.98 (95% confidence interval (CI) 0.74 to 1.30, P value 0.9) for surgery alone versus primary endocrine therapy; 0.86 (95% CI 0.73 to 1.00, P value 0.06) for surgery plus endocrine therapy versus primary endocrine therapy. The HRs for progression‐free survival were: 0.55 (95% CI 0.39 to 0.77, P value 0.0006) for surgery alone versus primary endocrine therapy; 0.65 (95% CI 0.53 to 0.81, P value 0.0001) for surgery plus endocrine therapy versus primary endocrine therapy (each comparison based on only one trial). Tamoxifen‐related adverse effects included hot flushes, skin rash, vaginal discharge, indigestion, breast pain, sleepiness, headache, vertigo, itching, hair loss, cystitis, acute thrombophlebitis, nausea, and indigestion. Surgery‐related adverse effects included paresthesia on the ipsilateral arm and lateral thoracic wall in those who had axillary clearance. One study suggested that those undergoing surgery suffered more psychosocial morbidity at three months postsurgery, although this difference had disappeared by two years. Primary endocrine therapy should only be offered to women with oestrogen receptor (ER) positive tumours who are unfit for or who refuse surgery. In a cohort of women with significant co‐morbid disease and ER‐positive tumours it is possible that primary endocrine therapy may be a superior option to surgery. Trials are needed to evaluate the clinical effectiveness of aromatase inhibitors as primary therapy for an infirm older population with ER‐positive tumours. 在患有可行手術原發性乳癌之年紀較大婦女(超過70歲)其使用手術與單獨內分泌療效之比較 許多研究已針對單獨作內分泌治療的臨床療效在符合手術條件且年紀大於七十歲的婦女做過探討。 由臨床隨機研究中的研究證據辨認與回顧單獨內分泌療法,與內分泌輔佐治療的手術及單純手術治療,在70歲及過了手術年齡之婦女的效果比較。 於2003年8月21日用 “早期的乳癌” “內分泌治療” “社會心理” 或 “手術” 等關鍵字在 Cochrane r乳腺癌小組專業搜索器中搜尋。 關於註冊與使用關鍵字搜索的流程細節可參考考科藍圖書館的考科藍乳癌小組。 比較主要內分泌療法(單獨內分泌療法)與手術在患有可行手術的原發性乳癌且年紀大於七十歲的婦女有或沒有佐藥內分泌療法的隨機試驗。 為了估計研究的合適性和質量,由二個獨立審閱者從出版試驗的數據來擷取。 用危險比率來看時間對事件的結果,若可能的話,固定作用模組使用來作整合分析。呈現擷取毒性和生活品質數據。 如果結果的數據不可利用的, 接洽測試者,並且請求未出版的數據。 在7個合格試驗中,已經確定了其中6個公佈了存活數據(timetoevent data),其中一個研究只公佈摘要格式,並且無有效數據。有三個研究,隨機分派的方式之隱匿性品質是充分的,但其他的研究方法不明。每一個研究之內分泌療法都使用他莫息芬(tamoxifen),資料中1571位婦女估計有869人死亡,但以整體存活(overall survival)來說無法顯現出以手術治療與單獨內分泌療法之間的統計顯著性。然而,使用單純手術治療或是手術伴隨內分泌治療之無病存活率(progressionfree survival)在統計上是顯著的。其整體存活之hazard ratios(HR): 單純使用手術治療與單獨內分泌治療之HR為0.98(95% 信賴區間(CI)為0.74 – 1.30, P value為0.9);以手術伴隨內分泌治療與單獨內分泌治療之HR為0.86(95% CI: 0.73 – 1.00, P value 0.06)。其無病存活之HRs為:單純使用手術治療與單獨內分泌治療之HR為0.55(95% CI: 0.39 – 0.77, P value0.0006);以手術伴隨內分泌治療與單獨內分泌治療(每單獨一個試驗相比)之HR為0.65(95% CI: 0.53 – 0.81, P...

This publication has 39 references indexed in Scilit: